Lappe Mark

SEC Form 4 insider
Chief Executive Officer · Inhibrx Biosciences, Inc. ($INBX)
1 thesis · first seen Sep 8, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d
3d
1w
1m
3m
6m
1y

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$INBXSEC Form 4bullish
Long 25,000 shares of INBX
Bought 25,000 @ $105.82 avg · $2,645,399 · 2026-09-08

Form 4: Lappe Mark bought INBX

Lappe Mark (Chief Executive Officer at Inhibrx Biosciences, Inc.) reported an open-market purchase of 25,000 shares of INBX at an average $105.82, roughly $2,645,399, in a Form 4 filed 2026-09-08.

View filing on SEC.gov →

End of results.